Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia

NCT03339700 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.

NCT NCT03339700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase
Phase 2
Overall status
Unknown status
Start date
September 15, 2018
Completion date
September 30, 2021
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult